Outlook Therapeutics (OTLK) EBIT: 2015-2024
Historic EBIT for Outlook Therapeutics (OTLK) over the last 10 years, with Sep 2024 value amounting to -$71.7 million.
- Outlook Therapeutics' EBIT rose 21.10% to -$10.0 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$36.8 million, marking a year-over-year decrease of 1.49%. This contributed to the annual value of -$71.7 million for FY2024, which is 34.97% down from last year.
- Latest data reveals that Outlook Therapeutics reported EBIT of -$71.7 million as of FY2024, which was down 34.97% from -$53.1 million recorded in FY2023.
- Outlook Therapeutics' EBIT's 5-year high stood at -$36.8 million during FY2020, with a 5-year trough of -$71.7 million in FY2024.
- For the 3-year period, Outlook Therapeutics' EBIT averaged around -$62.6 million, with its median value being -$63.1 million (2022).
- Per our database at Business Quant, Outlook Therapeutics' EBIT slumped by 40.41% in 2021 and then increased by 15.77% in 2023.
- Yearly analysis of 5 years shows Outlook Therapeutics' EBIT stood at -$36.8 million in 2020, then tumbled by 40.41% to -$51.7 million in 2021, then fell by 21.93% to -$63.1 million in 2022, then grew by 15.77% to -$53.1 million in 2023, then plummeted by 34.97% to -$71.7 million in 2024.